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Abstract The CCN family of proteins typically consists of
four distinct peptide domains: an insulin-like growth factor
binding protein-type (IGFBP) domain, a Von Willebrand
Factor C (VWC) domain, a thrombospondin type 1 repeat
(TSP1) domain, and a carboxy-terminal(CT) domain. The six
family members participate in many processes, including
proliferation, motility, cell-matrix signaling, angiogenesis,
and wound healing. Accumulating evidence suggests that
truncated and alternatively spliced isoforms are responsible
for the diverse functions of CCN proteins in both normal and
pathophysiologic states. Analysis of the properties and
functions of individual CCN domains further corroborates
this idea. CCN5 is unique among the CCN family members
because it lacks the CT-domain. To dissect the domain
functions of CCN5, we are developing domain-specific
mouse monoclonal antibodies. Monoclonal antibodies have
the advantagesofgreat specificity, reproducibility, and easeof
long-term storage and production. In this communication, we
injected mixtures of GST-fused rat CCN5 domains into mice
to generate monoclonal antibodies. To identify the domains
recognizedbythe antibodies,weconstructedserialexpression
plasmids that express dual-tagged rat CCN5 domains. All of
the monoclonal antibodies generated to date recognize the
VWC domain, indicating it is the most highly immunogenic
of the CCN5 domains. We characterized one particular clone,
22H10, and found that it recognizes mouse and rat CCN5, but
not human recombinant CCN5. Purified 22H10 was success-
fullyappliedinWesternBlotanalysis,immunofluorescenceof
cultured cells and tissues, and immunoprecipitation, indicat-
ing that it will be a useful tool for domain analysis and studies
of mouse-human tumor models.
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Abbreviations
IGFBP insulin-like growth factor binding module
VWC Von Willebrand Factor C module
TSP Thrombospondin type 1 repeat
I IGFBP domain
V VWC domain
T TSP1 domain
Introduction
Members ofthe CCN family ofproteinsplaya significant role
in a variety of critical cellular processes including cell
adhesion, migration, proliferation, gene expression, differen-
tiation, and survival (Bleau et al. 2005;K u b o t aa n dT a k i g a w a
2007;P e r b a l2004). CCN proteins fill this role, at least in
part, via interactions with extracellular matrix components
and growth factors (Chen and Lau 2008). With the exception
of CCN5, CCN proteins are defined by their four modular
domains: the insulin-like growth factor binding protein-like
domain (IGFBP), a Von Willebrand factor C-like domain
(VWC), a Thrombospondin 1 repeat domain (TSP-1) and a
C-terminal cysteine knot (CT). CCN5 is unique among the
family members in that it lacks the CT domain.
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domains has yielded important insights into mechanism. For
example, two CCN proteins—CCN1 and CCN2—bind to
integrins through the TSP-1/CT and VWC domains, and
appear to regulate a diverse array of biological functions,
including fibroblast adhesion, angiogenesis and MAPK
activation (Chen et al. 2004; Leu et al. 2004; Leu et al.
2003). Deletion of the CT domain abrogates the ability of
CCN3 to induce Notch signaling and inhibits osteogenic
differentiation and proliferation (Katsuki et al. 2008). In
addition, a naturally occurring isoform of CCN3 lacking the
TSP-1 domain relocates from the nucleus to the cytoplasm
of tumor cells in the renal neoplasm, Wilm’st u m o r
(Subramaniam et al. 2008). Recently, we discovered differ-
entially expressed isoforms of CCN5; exploration of the
structure-function relationships is now underway.
These studies, among others, indicate the importance of
studying CCN proteins not only at the level of the full-length
protein, but also at the level of the constituent domains. The
interaction and availability of ligand/receptors for each
individual domain, and the expression CCN variants via
mRNA splicing and/or post-translational modifications, may
helpexplainthediversefunctionsofCCNproteinsindifferent
cells and tissues (de Winter et al. 2008;H o l b o u r ne ta l .2008;
Rachfal and Brigstock 2005).
CCN5 is a unique member of the CCN family in that it is
the only family member lacking the C-terminal domain
(Delmolino et al. 2001; Pennica et al. 1998; Zhang et al.
1998). Altered CCN5 expression levels are associated with a
number of disease states including arterial restenosis, uterine
leiomyoma, and breast carcinoma (Banerjee et al. 2008;
Lake and Castellot 2003; Mason et al. 2004b). There is also
the suggestion that CCN5 expression is critical in develop-
ment, as transgenic pan-overexpression or pan-knockdown
of CCN5 in mice consistently results in embryonic lethality
(unpublished finding). Furthermore, studies utilizing adeno-
viral overexpression of CCN5 in vascular and uterine smooth
muscle cells have shown inhibition of SMC proliferation and
motility, both in vitro and in animal models, underscoring the
promise of this protein in future therapeutic uses (Lake et al.
2003; Mason et al. 2004b) Jones et al. 2007).
The availability of antibodies that recognize specific
epitopes within individual domains of CCN5 would be a
valuable tool for studying the structure-function relationship
of the three peptide domains of CCN5. Currently, the
antibodies used to detect CCNs are either affinity purified
rabbit polyclonal antibodies raised against peptide fragments
ofCCNproteins,orrabbitpolyclonalantibodiesraisedagainst
recombinant CCN proteins (Brigstock et al. 1997; Chevalier
et al. 1998;K u t ze ta l .2005;L a k ee ta l .2003; Steffen et al.
1998; Yang and Lau 1991; Zoubine et al. 2001). These
antibodies have proven highly useful in monitoring full
length CCN protein, but they are limited in their ability to
define the presence of individual domains (in the case of
polyclonal antibodies raised against peptide fragments), or
lack domain specificity (in the case of those raised against
recombinant protein). A clever alternative approach was used
by Perbal group, in which polyclonal antibodies were raised
against each domain of CCN3. These antibodies were then
used to define CCN3 isoform expression in a number of
different cancer samples (Lazar et al. 2007). We are aware of
only one report using monoclonal antibodies: Tamatani et al
used partially purified recombinant CCN2 to generate
monoclonal antibodies against CCN2 (Tamatani et al. 1998).
In this paper, we report our efforts to develop monoclo-
nal antibodies to the three domains of CCN5. To date, all of
the positive hybridoma clones isolated recognize the VWC
domain. Characterization of one of these antibodies,
22H10, indicates that it is a useful antibody for immuno-
blotting, immunofluorescence microscopy, and immunopre-
cipitation. The high degree of specificity, reproducibility,
and ease of producing large quantities of monoclonal
antibodies should make this approach a useful one for
domain analysis and other mechanistic studies.
Materials and methods
Cell culture
All cell were cultured at 37°C in a humidified, 5% CO2 /
95% air atmosphere. Sprague-Dawley aorta smooth muscle
cells were cultured using high glucose RPMI 1640 medium
(GIBCO) containing 10% bovine growth serum (BGS,
Hyclone), 2 mM L-glutamine (GIBCO), and 100ug/ml
penicillin/ streptomycin (GIBCO). BHK and 3T3 cells were
cultured in high glucose DMEM (GIBCO) containing 10%
BGS, L-glutamine, and penicillin/streptomycin. Hybridoma
clones were cultured in HAT hybridoma selection media
containing DMEM, 25% heat inactivated serum (Sigma
CPSR3), L-glutamine, penicillin/ streptomycin, HAT sup-
plement solution (hypoxanthine, aminopterin, thymidine;
Invitrogen), 7.8% NCTC-109 media (GIBCO), non-
essential amino acids (Hyclone). HT media is complete
DMEM containing HT supplement solution (hypoxanthine,
thymidine; Invitrogen). HI-DMEM media is same as
complete DMEM except that it contains heat-inactivated
fetal bovine serum (FBS, Hyclone). B-27 media is basal
DMEM with L-glutamine, penicillin/streptomycin, and B-27
supplement (GIBCO).
Sprague-Dawley rat aorta smooth muscle (SDSM) cells
were isolated as previously described (Lake et al. 2003).
SDSM were used at passage 8 or lower. Growth-arrest
of SDSM cells was accomplished by culturing cells for
72–96 h in RPMI containing only 0.4% serum plus
L-glutamine, and penicillin/streptomycin. Selected hybrid-
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limited dilution, then grown in HI-DMEM media. Stock
cultures were frozen in HI-DMEM with 10% dimethyl
sulfoxide (DMSO, SIGMA).
Construction of CCN5 expression plasmids
Eukaryotic expression plasmids for recombinant human,
mouse, and rat CCN5
Human, mouse CCN5 ORFs were PCR amplified from
IMAGE clones purchased from Open Biosystems (human:
MHS1011-7509651; mouse: MMM1013-7510036). Rat
CCN5 ORF was PCR amplified from cDNA samples derived
from growth-arrested SDSM cells. The primers are listed as
pair 9 and 10 in Table 1. Gene cloning was accomplished
using the Gateway System (Invitrogen, K2400-20). Briefly,
PCR fragments of CCN5 ORFs were inserted into entry
vector pENTR/D-TOPO. After sequence verification, the
inserts were switched into the destiny vector pcDNA-
DEST40 for eukaryotic cell expression. The recombinant
CCN5 proteins were tagged at the C-terminus with one V5
epitope and six histidines. The recombinant CCN5 proteins
utilized the endogenous CCN5 signal peptide for secretion.
Eukaryotic expression plasmids for dual-tagged rat CCN5
domains
Each of the rat CCN5 domains and domain combinations
were PCR amplified from the rat entry plasmid cloned above.
Primer pairs used for cloning are indicated in Fig. 1.P r i m e r
sequences and XbaI/HindIII linkers are shown in Table 1.T o
make the IT domain, an XhoI site was added in frame. All
PCR fragments were cloned into pCR2.1-TOPO vector
(Invitrogen, 45-0641) for sequencing and further sub-
cloning. The DNA of each domain was excised with XbaI
and HindIII, and then ligated into the expression vector
pflag-myc-CMV 20 (SIGMA, E5526). As shown in Table 2,
the resulting proteins all have a flag tag (DYKDDDDK) in
the N-terminus and a c-myc tag (EQKLISEEDL) in the
C-terminus. These plasmids were used to screen for positive
hybridoma clones and for mapping the epitope of anti-CCN5
antibodies.
Bacterial expression plasmids for GST-fused CCN5
domains
The rat CCN5 domains I, V, T, IV and IVT in pCR2.1-
TOPO vectors were sub-cloned in-frame into pGEX-4T-1
vector (Amersham-GE Healthcare, 27-4580-01) between
the EcoRI and XhoI restriction sites.
Bacterial expression of GST-fusion proteins
High-level bacterial expression of GST-fused proteins
and inclusion body isolation followed the protocol
described by Shi et al. (Shi et al. 2008). Briefly,
transformed protease-deficient E. coli host strain BL21
(DE3) (Novagen) clones were selected by ampicillin, and
then cultured in 37°C until the O.D. was 0.6 units. GST-
fusion protein expression was further induced by culturing
for 4 h in media containing 0.5 mM isopropyl-β-d-
thiogalactoside (IPTG). The bacterial pellet was lysed by
several rounds of sonication in PBS followed by centrifu-
gation at 5000xg for 5 min to pellet the inclusion bodies.
The purified inclusion bodies were resuspended in equal
amount of PBS and a small portion of was analyzed by
SDS-PAGE.
Primer ID Direction Linker Sequence
1 Forward HindIII AAGCTT GTGTGTGCCCAGCTGTGCCG
2 Reverse XbaI TCTAGA GAGACACACAGCCCCATGGCCG
3 Forward HindIII AAGCTT TTGGATGAGGATGACGGTAGC
4 Reverse XbaI TCTAGA TTGCGCCGCGGAGCGCTGGAT
5 Forward HindIII AAGCTT GGACACCAACTTTCTGCCCT
6 Reverse XbaI TCTAGA GAAAGCACTGTTCCATGAGCTG
7 Reverse XhoI CTCGAG GAGACACACAGCCCCATGGCCG
8 Forward XhoI CTCGAG GGACACCAACTTTCTGCCCT
9 human Forward CACC CACC ATGAGAGGCACACCGAAGAC
10 human Reverse N/A GAAGGCACTGTTTTGTGGACT
9 mouse Forward CACC CACC ATGAGGGGCAACCCACTG
10 mouse Reverse N/A GAAGGCACTGTTCCATGAGC
9 rat Forward CACC CACC ATGAGGGGCAGCCCACT
10 rat Reverse N/A GAAAGCACTGTTCCATGAGC
Table 1 Sequences of primers
shown in Fig. 1
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hybridomas
Immunizations and fusions were done essentially as described
(Harlow and Lane 1988;P r e s t o ne ta l .2008)w i t hs o m e
modifications. The isolated GST-fusion proteins were grouped
into two groups: one group contained GST-I, GST-V, GST-T,
and the other group contained GST-IV and GST-IVT. Each
group was injected into two Swiss Webster and two Balb/c
mice. The initial injection into the footpad of mice used 100ul
1:100 dilution of purified inclusion bodies. This was followed
by four additional abdominal injections, three weeks apart, of
smashed SDS-PAGE gel slices of GST-fusion protein bands.
Seven days after the final injection, tail vein blood was drawn
to check for anti-CCN5 positive serum. Splenocytes from
serum-positive mice were dissociated and mixed with NSOI
myeloma cells. A 50% Polyethylene glycol solution
(PEG1500, 50% w/v in 75 mM HEPES, Boehringer
Mannheim) was added slowly to the cell pellet with gentle
mixing in a 37°C water bath and incubated for 90 more
seconds, after which warm DMEM was added drop-by-drop.
Finally, cells were diluted into complete HAT media and
aliquoted into 96-well plates. Cells were cultured for 10 days
without changing media until visible clones had formed.
Screening of hybridomas was carried out using immu-
nofluorescence microscopy on transfected cells grown on
24-well slides as described below. Cultured cells (either
3T3 or BHK) were transfected with the dual-tagged CCN5
domain constructs. Protein expression was verified by anti-
myc antibody (9E10, McKeon lab). Positive clones were
subcloned, expanded, and frozen down in liquid nitrogen.
Purification of monoclonal antibody
Hybridoma cells were grown in B-27 media for 3 weeks.
Antibodies were purified from the supernatant by affinity
chromatography. Briefly, supernatant was mixed 3:1 with
bindingbuffer(50mMTris-Cl,150mMNaCl,0.05%sodium
azide, pH7.4) plus phenylmethylsulfonyl fluoride (PMSF) to
final concentration of 0.5 mM. Protein G Sepharose 4 Fast
Flow beads (GE Healthcare, 17-0618-01) were added to the
solution and gently rotated at 4°C overnight. Protein G beads
were packed into a column and washed twice with binding
buffer plus PMSF. Pure IgG was eluted with 0.1 M glycine,
pH2.7. Each 450μl of elution were collected into tubes
containing 50μl 1 M Tris-Cl, pH9.0. The protein concentra-
tion of each fraction was assessed spectrophotometrically at
A280. The tubes containing the highest amount of protein
were combined and concentrated using the Millipore Amicon
Ultra-15 centrifugal filter (Millipore, UFC901024). The
concentrated antibody was then replaced into 50% glycerol
in PBS storage buffer. Protein concentration was determined
byabsorbanceatA280usinga Nanodropinstrument(Thermo
Scientific), and adjusted to 1 mg/ml.
Plasmid transfection and immunofluorescence microscopy
Cells (BHK and 3T3) were transfected with Lipofectamine
2000 (Invitrogen) according to a modification of the
manufacturer’s protocol. Exponentially growing cells were
trypsinized, re-suspended in transfection media (DMEM
media with 10% BGS and L-Glutamine), plated onto multi-
well slides (Erie Scientific), and allowed to grow to 70–
80% confluence. In each 9 mm well, 0.2μg DNA and 0.4 ul
Lipofectamine were mixed in 10ul Opti-MEM media
(GIBCO) and incubate at room temperature for 20 min,
and then diluted with 150ul transfection media. The
mixture was added onto the cells of each well. Cells were
cultured with this mixture for 16–24 h, and then replaced
with normal medium for another 24–48 h.
Domains Primers PCR size (bp) Fusion proteins Predicated protein size (kda)
I 1+2 228 flag-I-myc 10.2
V 3+4 267 flag-V-myc 12.2
T 5+6 231 flag-T-myc 10.7
IV 1+4 483 flag-IV-myc 19.7
VT 3+6 486 flag-VT-myc 20.2
IT 1+7, 8+6 453 flag-IT-myc 18.4
IVT 1+6 702 flag-IVT-myc 27.6
Table 2 Primer pairs for
dual-tagged rat CCN5 domain
constructs and their product
sizes
Fig. 1 Rat CCN5 domain primer design. Each primer is designated
by a number, and the same color denotes identical primers. Each
domain was amplified using the primer pairs shown here. Domain IT
is a domain generated by joining domains I and T together, separated
by an XhoI site linker. Full-length CCN5 amplifies the entire open-
reading-frame
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were transfected in 100 mm dishes and then trypsinized. 2–
3×10
3 cells were aliquoted onto each well of 24-well glass
slides and cultured for additional 16–24 h. After fixation
and permeabilization, slides were stored in 50% glycerol in
PBS at−20°C. Slides can be stored in these conditions for at
least 2 weeks without loss of expressed proteins. For each
100 mm dish, 20ug of DNA and 40ul Lipofectamine in
500ul Opti-MEM was used instead.
Transfected cells were fixed with 3% formaldehyde in
PBS for 7–10 min, then permeabilized by washing three
times with 1x PBST (PBS containing 0.1% Triton X−100)
for 3 min each. Wells were washed with PBS three times
before adding primary antibody. Unless noted, primary
antibodies were normally diluted 1:100 in PBS, and the
secondary antibody (AlexaFluor 594 goat-anti-mouse,
Invitrogen) was diluted 1:1000 in PBS. Cells were
incubated with antibodies for 1 h at room temperature. Cell
nuclei were visualized using DAPI (1μg/ml in PBS for
5 min). All washing steps between incubations were done 3
times with PBS for 5 min each, unless otherwise noted.
Slides were mounted with 90% Glycerol in 10 mM Tris-Cl,
pH7.4. Pictures were taken on a Carl Zeiss Axio fluores-
cent microscope and analyzed by AxioVersion software.
Western Blot analysis
We followed the protocol previously described (Lake et al.
2003). Briefly, cultured cells were washed twice with cold
PBS for 5 min each, then lysed with RIPA buffer (1% NP-
40, 0.5% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl,
0.05 M Tris-HCl, pH7.5) plus 1:50 protease inhibitor
(Sigma, P8340). Proteins were denatured at 95°C for 5 min
with 2X loading buffer (100 mM Tris-Cl, pH6.8, 4% SDS,
20% glycerol, 200 mM DTT, 0.2% Bromophenol Blue), and
then separated by 12% SDS-PAGE and transferred onto 0.2-
μm pore size Immuno-Blot polyvinylidene difluoride mem-
branes (PVDF, Bio-Rad). Dried membranes were rewetted
and blocked with 5% non-fat milk in TBST (137 mM NaCl,
20 mM Tris, pH7.6, 0.2% Tween 20). The purified antibody
22H10 was diluted 1:2000 in milk-TBST; other antibodies
were diluted 1:1000 in milk-TBST; horseradish peroxidase
(HRP)-conjugated secondary antibody anti-mouse or anti-
rabbit IgG (Santa Cruz) was diluted 1:5000. All washing
steps were done three times with PBST for 10 min each.
Membranes were developed with ECL reagent (GE-Amer-
sham, RPN2132), and exposed with X-Omat Blue XB-1
Film (Kodak).
Immunoprecipitation
Cell lysates were prepared as described above for Western
Blot analysis. Primary antibodies (22H10 and control
mouse IgG) and cell lysates was incubated overnight at
4°C with gentle agitation then incubated with Protein G
Sepharose 4 Fast Flow beads for 1 h at room temperature.
The protein-antibody-bead complex was spun down at
2000 × g for 2 min, and the resulting pellet was washed six
times with RIPA buffer containing protease inhibitor.
Finally, the protein complex was denatured in loading
buffer at 95°C for 2 min and analyzed by Western Blot.
Membranes were stained with Ponceau S staining (0.2%
Ponceau S, 1% acetic acid) to visualize proteins.
Immunofluorescence microscopy with Dylight 594-labeled
primary antibodies
Equal amounts of purified 22H10 and control mouse IgG
(Bethyl Laboratories) were directly conjugated with Dylight
594 fluorescent dye using the Dylight Antibody Labeling
Kit (Pierce). After labeling and purification, protein and dye
incorporation were determined using a Nanodrop instru-
ment to ensure equal application of 22H10 and control
mouse IgGs on tissue sections.
The immunofluorescence microscopy protocol and
paraffin-embedded rat intestine sections were kindly provided
by Wen-Chi Yang in Dr. McKeon’s laboratory at Harvard
MedicalSchool.Briefly,smallintestineandcolonof6–8week
old female rats were isolated and fixed overnight in 3.7%
formaldehyde at 4°C, then put into 70% ethanol until use.
Tissues were paraffin embedded and sectioned at the Harvard
Rodent Histological Center. Sections were de-paraffined and
re-hydrated through xylene, 100% ethanol, 95% ethanol, and
PBS. Antigen retrieval was done by immersing the slides
in10mM citrate for 15–20 min at 92.8°C, followed by slow
cooling to room temperature before transfer into PBS.
Sections were blocked for 30 min at room temperature with
PBS containing 10% BSA and 1:100 normal mouse serum.
Dylight594labeledprimaryantibodieswereaddedatdifferent
dilutions in PBS onto each section, and incubated overnight at
4°C. Slides were washed with PBST (PBS with 0.1% tween-
20) three times for 5 min each. Cell nuclei were visualized
using DAPI (1μg/ml in PBS for 5 min). Slides were mounted
using 90% Glycerol in 10 mM Tris-Cl, pH7.4. Pictures were
taken using a Zeiss Axio fluorescence microscope and
analyzed by AxioVersion software.
Results
Production and screening of anti-CCN5 monoclonal
antibodies
To obtain the monoclonal antibodies against each domain
of rat CCN5, we first expressed rat CCN5 domains as GST-
fusion proteins in the bacterial strain BL21. After IPTG
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inclusion bodies and isolated by sonication and centrifuga-
tion. Following SDS-PAGE, Coomassie staining (Fig. 2)
revealed that the dominant bands appeared at the predicted
sizes of the fusion proteins, and were confirmed to be
CCN5 using a specific rabbit anti-CCN5 polyclonal
antibody, NGRR, raised against a peptide fragment of the
rat CCN5 VWC domain NGRRYLDGETFKPNC, same
region as human CCN5 previously described (Gray et al.
2007; Jones et al. 2007; Lake et al. 2003; Mason et al.
2004a). The additional bands visible in the Western blot are
the result of insufficient reduction of compacted proteins in
the inclusion bodies.
Mice were immunized with a mixture of GST-fused
CCN5 domain proteins as described in Material and
Methods. Swiss Webster mice were more immunogenic
than Balb/c mice, with 3 out of 4 positive for anti-CCN5
antibodies after four injections compared with 1 out of 4
testing positive for production of CCN5 antibodies (data
not shown). In addition, and not unexpectedly, we found
that the larger proteins were more immunogenic than
smaller proteins: only 1 of the 4 mice injected with a
mixture of GST fusion peptides linked to the individual I,
V, and T domains were positive for anti-CCN5 antibodies,
whereas 3 of 4 mice injected with a mixture of GST fusion
peptides linked with the IV and IVT domains produced
anti-CCN5 antibodies (not shown).
Two of the Swiss Webster mice that were positive for
anti-CCN5 antibodies were sacrificed and their spleen cells
fused with myeloma cells. After selection in HAT media for
10 days, single hybridoma clones were visible and the
supernatant from wells containing single clones was
combined and screened as described in Material and
Methods. We used immunofluorescence microscopy of
BHK cells transfected with plasmids expressing dual-
tagged domain proteins to screen monoclonal antibodies,
thus eliminating the many false positives against GST seen
in screening methods using Western Blot analysis with the
GST-fusion protein.
All identified monoclonal antibodies are against
the V-domain of CCN5
Following two rounds of screening, 32 clones were
identified that produced anti-CCN5 antibodies. Further
mapping of the antibodies’ targeted epitopes on CCN5 by
Western blot using GST-fused CCN5 domain proteins
showed that all clones produced antibodies against the V
domain of CCN5 (not shown). We picked one clone,
22H10, with a particularly high antibody titer among the
hybridoma clones, for expansion, purification, and further
characterization. All other clones were placed into liquid
nitrogen storage for future analysis and use.
Antibody 22H10 characterization demonstrates
that it recognizes the V-domain
To isolate purified 22H10 antibody, hybridoma clone
22H10 was grown in B-27 supplemented DMEM for
3 weeks to produce maximum antibody titer, purified by
protein G-conjugated Sepharose beads, and subjected to
SDS-PAGE analysis (Fig. 3). To determine which epitope
the antibody was directed against, we carried out both
immunofluorescence microscopy and Western Blot analysis
of purified 22H10 antibody (Fig. 4). The antibody
recognized all dual-tagged rat CCN5 domain constructs
containing the V domain of CCN5, but none of the
constructs without the V domain. Expression of all dual-
labeled domains was confirmed by both anti-Flag and anti-
Myc antibody staining and Western Blot analysis (Fig. 4).
These data indicate that antibody 22H10 is directed against
the V-domain of CCN5.
22H10 immunoprecipitates recombinant and endogenous
CCN5 protein
Having determined that the 22H10 antibody could detect
the V-domain of CCN5 in both immunofluorescence and
Western Blot analyses, we assessed whether or not the
Fig. 2 Purified inclusion bodies
of BL21 express GST-fused rat
CCN5 domains. a Coommassie
staining of samples run on re-
ducing SDS-PAGE gels. b
Western Blot analysis using the
polyclonal anti-CCN5 antibody
NGRR, raised against a peptide
from V-domain of rat CCN5
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would be a potentially useful characteristic for future
studies. Compared to the mouse IgG control, 22H10 was
able to recognize both recombinant and endogenous CCN5
(Fig. 5a). It was also able to precipitate recombinant CCN5
from lysates of 3T3 cells expressing flag-IVT-myc protein
(Fig. 5b), and endogenous CCN5 from growth arrested rat
aortic smooth muscle cells (Fig. 5c). Mouse IgG controls
neither recognized nor precipitated CCN5. The previously
described rabbit polyclonal anti-CCN5 peptide antibody
NGRR confirmed the expression of both recombinant
(Fig. 4b) and endogenous CCN5 (Fig. 5c).
22H10 reacts with mouse and rat CCN5, but not human
CCN5
To test the specificity of 22H10 antibody on different
species, we cloned human, mouse and rat CCN5 into the
Gateway expression vector. V5 and 6XHis tags were
included in C-terminal of the recombinant protein. The
human and mouse sequences were cloned from the
Integrated Molecular Analysis of Genomes and their
Expression (IMAGE) Consortium clones distributed by
Open Biosystems (http://image.hudsonalpha.org/), while
the rat CCN5 sequence was cloned from growth arrested
SDSM cells as described in Materials and Methods. All
plasmids were sequenced for identity and accuracy before
using them in the cloning procedure. β-galactosidase was
cloned and used as a negative control. 22H10 antibody
recognized rat and mouse CCN5 recombinant proteins, but
not human CCN5, in both immunofluorescence (Fig. 6a)
and Western Blot analyses (Fig. 6b). As expected, LacZ
was not recognized by 22H10 antibody.
22H10 detects endogenous mouse CCN5 in tissues
The ability of 22H10 antibody to recognize CCN5 in
tissues was assessed by direct application of Dylight 594
conjugated primary antibodies to rat intestine sections.
Compared to mouse IgG controls, 22H10 antibody stained
strongly for rat intestine epithelium. Other cell types had
less staining compare to epithelium (Fig. 7). Interestingly,
at higher magnification, the nuclear staining of 22H10 in
smooth muscle cells and fibroblasts are readily apparent
compared to mouse IgG controls. Similar results were seen
in rat colon (data not shown). This result indicates that
22H10 displays the same expression pattern in mouse as
other anti-CCN5 antibodies previously used in embryos
(Jones et al. 2007) and adult mice (Gray et al. 2007).
Discussion
In this paper, we report the generation of monoclonal
antibodies directed against specific domains of the CCN5
protein. A total of 32 monoclonal antibodies against rat
CCN5 were generated in this study. Although they are all
against V domain of CCN5, they require further character-
ization to determine their relative specificity and uses. The
possibility that one or more of the clones might be
producing function-blocking antibodies remains intriguing,
as does the possibility that some of the antibodies may react
with human CCN5. Many of the other reagents generated in
this study should be useful tools as well. The dual-tagged
CCN5 domain constructs may be used in studies of
isoforms and domains of CCN5. The GST-fused proteins
have applications in the study of CCN5 function both in
vitro and in vivo.
One useful technical feature of the monoclonal antibody
process we designed is the use of immunofluorescence
microscopy of transfected BHK cells grown on 24-well
glass slides to detect anti-CCN5 positive hybridoma clones.
This proved to be much more efficient in terms of both time
and labor compared to the standard approaches that use
ELISA or Western Blot analysis to screen hybridoma
clones. Using the preparation and preservation conditions
described in Materials and Methods, samples can be stored
for at least 2 weeks.
We purified and characterized one anti-CCN5 monoclo-
nal antibody, 22H10, and found that it is specific for the
V-domain. It recognizes and reacts with mouse and rat
CCN5 and V-domains, but not human. This species
specificity profile suggests that it will be useful in human-
mouse grafts to distinguish the mouse cells from the
human. Importantly, we demonstrate that 22H10 recognizes
and reacts with endogenous CCN5 as well recombinant
protein. Since 22H10 can immunoprecipitate as well as
identify CCN5, it may be useful in identifying CCN5
binding partners and other interacting proteins.
Though we designed the monoclonal antibody genera-
tion to produce antibodies against each domain of CCN5 by
immunizing mice with a mixture of GST-fused domains, we
Fig. 3 Coommassie staining of
purified 22 h10. Hybridoma
clone 22H10 was grown in B-27
supplement media for 3 weeks.
Cells were lysed and the
lysate applied to a Protein
G-conjugated agarose column.
Bound material was eluted from
the column and run on12%
reduced SDS-PAGE. The upper
band is IgG heavy chain
(~50Kda), and lower band is
light chain (~24 Kda)
Monoclonal antibodies to CCN5 71Fig. 4 22H10 recognizes the
V-domain of CCN5. Rat CCN5
domains are expressed by trans-
fected plasmids in 3T3 cells. All
proteins are tagged with flag at
N-terminal and c-myc at the
C-terminal. Labels are 0 mock,
1 flag-I-myc, 2 flag-V-myc,
3 flag-T-myc, 4 flag-IV-myc, 5
flag-VT-myc, 6 flag-IT-myc, 7
flag-IVT-myc A. proteins
detected by immunofluores-
cence microscopy. Each anti-
body stained separately, DAPI
shows the typical cell density. B.
expressed dual-tagged domain
proteins are detected by Western
blot. Lysates of each domain
construct transfected 3T3 cells
are indicated as each lane. Note
a cloning error make I domain
do not have c-myc tag, hence
not detected by anti-myc
antibody
72 L. Wei et al.Fig. 5 22H10 recognizes and
immunoprecipitates recombi-
nant CCN5 and endogenous
CCN5. Mouse IgG serves as
control for immunoprecipitation
and western blot. GAPDH and
Ponceau staining show the equal
loading of proteins. A. 22H10
recognizes flag-IVT-myc and
CCN5 in growth arrested SDSM
cells. B. 3T3 cells were trans-
fected with plasmid expressing
flag-IVT-myc for 48 h. Cells
were lysed and immunoprecipi-
tated with 22H10 and detected
using anti-myc antibody.
Immuno-complexes were disso-
ciated in reducing loading buffer
and run on 12% SDS-PAGE gel.
C. SDSM cells were cultured
using conditions that rendered
them quiescent (G0) or allowed
them to proliferate exponentially
(Exp). Cells were lysed and
immunoprecipitated with
22H10, and CCN5 was detected
using NGRR antibody
Monoclonal antibodies to CCN5 73did not detect the spectrum of antibodies against each
domain of CCN5 as we had anticipated. Instead, all of the
antibodies are against epitopes in the V-domain of CCN5.
This suggests that the V-domain is more immunogenic than
the other domains. Of note is that when the CCN5 amino
acid sequence is analyzed to reveal the most immunogenic
regions, a 14 amino acid sequence in the V-domain was
identified, and that is what we used to generate rabbit
polyclonal anti-CCN5 antibody NGRR. This is not entirely
unexpected: the immunogenicity of the V-domain has also
been demonstrated in other CCN family members. For
example, in CCN2, computer-assisted prediction of epitome
immunogenicity indicates that the V-domain and CT
domain (which is absent in CCN5) are the most highly
immunogenic (Minato et al. 2004). Further, injection of
full-length recombinant CCN2 into mouse and rabbits, the
majority of antibodies generated recognized the V-domain
of CCN2 (Minato et al. 2004). Future efforts to produce
domain-specific monoclonal antibodies are much more
likely to be successful if only the I-domain, T-domain, or
amino acid sequences contained within these domains, are
used as antigens. Nor is the monoclonal approach to
antibody generation the only viable option. By injecting
the domain peptides separately, Perbal and colleagues
Fig. 6 22H10 reacts with
mouse and rat CCN5, but not
with human recombinant CCN5.
3T3 cells were transfected with
plasmids that express V5-tagged
CCN5 of the indicated species.
A. Immunofluorescence micros-
copy of 3T3 cells. B. 3T3 cell
lysates were subjected to
Western Blot analysis. 22H10
recognizes mouse and rat, but
not human recombinant CCN5
74 L. Wei et al.succeeded in generating rabbit polyclonal antibodies
against each domain of CCN3 (Lazar et al. 2007), and this
remains a viable approach to CCN5 domain analysis as
well.
We used direct dye labeling of primary antibodies and
application to tissue sections. This method eliminates
non-specific signals caused by endogenous peroxidase and
non-specific binding of anti-mouse secondary antibody.
Although this approach is not as sensitive as immunohis-
tochemistry and indirect immunofluorescence, we were
able to visualize CCN5 staining quite easily in tissue
sections with direct-labeled 22H10. Taken together, the data
presented in this communication on the characterization of
22H10 indicates that it is a highly specific monoclonal
antibody that will be useful for a variety of applications in
the study of CCN5.
Fig. 7 22H10 recognizes CCN5 in vivo. Immunofluorescence micros-
copy using 22H10 directly conjugated to Dylight 594 fluorescent dye
was carried out on paraffin embedded rat intestine cross sections.
Sections are blocked using PBS containing 10% BSA and 1:100 normal
mouse serum. Dylight 594 labeled antibodies are diluted 1:100 in PBS.
A. Lower magnification shows the structure of intestine and the strong
staining of the epithelium by 22H10. B. At higher magnification,
nuclear staining was more apparent in other cell types. This staining
pattern in rat GI track is the same as another anti-CCN5 antibody
(NGRR) previously reported in mouse embryo and adult tissues
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